Press Release
New Data Demonstrates ProMark™ Accurately Predicts Prostate Cancer Aggressiveness and Pathological Outcomes
ProMark™ has Potential to Transform Prostate Cancer Care by Aiding Doctors and Patients with Appropriate Treatment Assessment
read article
Press Release
METAMARK GENETICS RECEIVES LABORATORY LICENSE IN PREPARATION TO LAUNCH ProMark™ PROSTATE-CANCER ASSAY
Metamark Genetics, Inc. today announced that its Cambridge, Mass. laboratory has been licensed for the highest level of clinical testing in the use of ProMark™, the company's prognostic assay to guide the medical management of patients with prostate cancer.
read article